Sean  Salmon net worth and biography

Sean Salmon Biography and Net Worth

EVP of Medtronic
Sean Salmon serves as Executive Vice President and President for the Diabetes Operating Unit (OU) and President for the Cardiovascular Portfolio.

In this dual role, Sean is responsible for the overall strategic direction of the Diabetes OU and its day-to-day global operations. He is also responsible for optimizing Medtronic enterprise performance by supporting capital allocation, talent management, investments, and collaboration to create value across all eight OUs that are organized under the Cardiovascular Portfolio, in addition to the Diabetes OU.

Sean joined Medtronic in 2004 and has held increasingly senior management roles. Most recently as President of Coronary & Structural Heart within our Cardiovascular Portfolio, he led numerous functions including Clinical, Regulatory, R&D, Quality, Health Economics & Reimbursement, Business Development and Strategy. He led Medtronic’s entry into the highly-competitive drug eluting stent market and subsequently diversified the business via organic innovation and acquisitions. He also led the expansion of Medtronic’s fast-growing transcatheter valve replacement (TAVR) business by commercializing multiple product innovations, extending global penetration and by expanding treatment indications.

Sean has nearly 30 years’ experience in the medical device and pharmaceutical industries, with previous roles at C.R. Bard, Johnson & Johnson, SurgiVision and EuroRSCG Life. He earned an MBA from the Kellogg School of Management at Northwestern University and a BS in Applied Physiology from Boston University.

What is Sean Salmon's net worth?

The estimated net worth of Sean Salmon is at least $3.91 million as of February 21st, 2024. Mr. Salmon owns 48,289 shares of Medtronic stock worth more than $3,913,341 as of June 15th. This net worth approximation does not reflect any other investments that Mr. Salmon may own. Additionally, Mr. Salmon receives an annual salary of $900,970.00 as EVP at Medtronic. Learn More about Sean Salmon's net worth.

How old is Sean Salmon?

Mr. Salmon is currently 59 years old. There are 5 older executives and no younger executives at Medtronic. The oldest executive at Medtronic is Mr. Robert J. W. ten Hoedt, Executive VP & President of Global Regions, who is 64 years old. Learn More on Sean Salmon's age.

What is Sean Salmon's salary?

As the EVP of Medtronic plc, Mr. Salmon earns $900,970.00 per year. There are 4 executives that earn more than Mr. Salmon. The highest earning executive at Medtronic is Mr. Geoffrey Straub Martha, Chairman of the Board & CEO, who commands a salary of $1,790,000.00 per year. Learn More on Sean Salmon's salary.

How do I contact Sean Salmon?

The corporate mailing address for Mr. Salmon and other Medtronic executives is 20 ON HATCH LOWER HATCH STREET, DUBLIN L2, D02. Medtronic can also be reached via phone at (531) 438-1700 and via email at [email protected]. Learn More on Sean Salmon's contact information.

Has Sean Salmon been buying or selling shares of Medtronic?

Sean Salmon has not been actively trading shares of Medtronic during the past quarter. Most recently, Sean Salmon sold 30,695 shares of the business's stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $85.13, for a transaction totalling $2,613,065.35. Following the completion of the sale, the executive vice president now directly owns 48,289 shares of the company's stock, valued at $4,110,842.57. Learn More on Sean Salmon's trading history.

Who are Medtronic's active insiders?

Medtronic's insider roster includes Richard Anderson (Director), Michael Coyle (EVP), Gary Ellis (EVP), Hooman Hakami (EVP), Bryan Hanson (EVP), Omar Ishrak (Chairman), Richard Kuntz (SVP), Bradley Lerman (SVP), John Liddicoat (EVP), Michael Marinaro (EVP), Geoffrey Martha (CEO), Karen Parkhill (CFO), Sean Salmon (EVP), Gregory Smith (EVP), Carol Surface (SVP), Rob Ten Hoedt (EVP), Brett Wall (EVP), Brett Wall (EVP), and Robert White (EVP). Learn More on Medtronic's active insiders.

Are insiders buying or selling shares of Medtronic?

During the last year, insiders at the medical technology company sold shares 9 times. They sold a total of 75,525 shares worth more than $6,384,605.25. The most recent insider tranaction occured on June, 7th when CEO Geoffrey Martha sold 19,113 shares worth more than $1,601,096.01. Insiders at Medtronic own 0.3% of the company. Learn More about insider trades at Medtronic.

Information on this page was last updated on 6/7/2024.

Sean Salmon Insider Trading History at Medtronic

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/21/2024Sell30,695$85.13$2,613,065.3548,289View SEC Filing Icon  
12/13/2022Sell16,631$80.50$1,338,795.5036,088View SEC Filing Icon  
8/25/2021Sell28,419$134.08$3,810,419.5254,458View SEC Filing Icon  
See Full Table

Sean Salmon Buying and Selling Activity at Medtronic

This chart shows Sean Salmon's buying and selling at Medtronic by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Medtronic Company Overview

Medtronic logo
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $81.04
Low: $80.52
High: $81.54

50 Day Range

MA: $82.01
Low: $79.08
High: $85.92

2 Week Range

Now: $81.04
Low: $68.84
High: $91.00

Volume

3,678,571 shs

Average Volume

6,862,874 shs

Market Capitalization

$107.61 billion

P/E Ratio

29.47

Dividend Yield

3.38%

Beta

0.83